Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651084 | 0.85 | DDB1 (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24132058 | 0.84 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20812400 | 0.83 | CRBN (1.00) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL26049315 | 0.82 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL22609484 | 0.82 | CRBN (0.97) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL25653922 | 0.81 | CRBN (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL18945869 | 0.81 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23066127 | 0.81 | CRBN (0.55) | DDB1CRBNIKZF3TNF | |
| SCHEMBL18509320 | 0.81 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282494 | 0.81 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021121261-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | 北京泰德制药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021036922-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | 北京泰德制药股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | DDB1 2765/4885CRBN 898/4885IKZF3 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.